Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Lenalidomide and Ixazomib: a successful amyloidosis treatment combination?

Oliver Charles Cohen • 14 Sep 2019
IMW 2019
Amyloidosis Multiple Myeloma Rare Diseases Daratumumab Ixazomib Lenalidomide
ANDROMEDA

Dr Oliver Charles Cohen, MD, of the University College London Hospitals NHS Foundation Trust, London, UK, discusses the challenges of amyloidosis, and the newfound promise of lenalidomide combined with ixazomib in its treatment. This interview was recorded at the International Myeloma Workshop (IMW) 2019, in Boston, MA.

More from Oliver Charles Cohen

3:01
The value of screening biopsies in AL & ATTR amyloidosis
Oliver Charles Cohen • 15 Sep 2020
4:05
Post-renal transplantation hematological response assessment: AL amyloidosis
Oliver Charles Cohen • 16 Sep 2020

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals